Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2020

01-12-2020 | Diabetic Nephropathy | Research article

Kidney-targeted baicalin-lysozyme conjugate ameliorates renal fibrosis in rats with diabetic nephropathy induced by streptozotocin

Authors: Xiao-peng Zheng, Qing Nie, Jing Feng, Xiao-yan Fan, Yue-lei Jin, Guang Chen, Ji-wei Du

Published in: BMC Nephrology | Issue 1/2020

Login to get access

Abstract

Background

Diabetic nephropathy (DN) is one of the most common and serious complications of diabetes, and is the most important cause of death for diabetic patients. Baicalin (BAI) has anti-oxidative, anti-inflammatory and anti-apoptotic activities, which play a role in attenuating insulin resistance and protecting the kidney. Moreover, cell-specific targeting of renal tubular cells is an approach to enhance drug accumulation in the kidney.

Methods

Forty-five Sprague-Dawley rats were divided into four groups. A diabetes model was created using streptozotocin (STZ) intraperitoneally injection. The four groups included: Control group (n = 10), DN (n = 15), BAI treatment (BAI; n = 10) and BAI-LZM treatment (BAI-LZM; n = 10) groups. In the current study, the renoprotection and anti-fibrotic effects of BAI-lysozyme (LZM) conjugate were further investigated in rats with DN induced by STZ compared with BAI treatment alone.

Results

The results suggest that BAI-LZM better ameliorates renal impairment, metabolic disorder and renal fibrosis than BAI alone in rats with DN, and the potential regulatory mechanism likely involves inhibiting inflammation via the nuclear factor-κB signaling pathway, inhibiting extracellular matrix accumulation via the transforming growth factor-β/Smad3 pathway and regulating cell proliferation via the insulin-like growth factor (IGF)-1/IGF-1 receptor/p38 Mitogen-activated protein kinase (MAPK) pathway. BAI and the kidney-targeted BAI-LZM can utilize the body’s cytoprotective pathways to reactivate autophagy (as indicated by the autophagy markers mechanistic target of rapamycin and sirtuin 1 to ameliorate DN outcomes.

Conclusions

Our data support the traditional use of S. baicalensis as an important anti-DN traditional chinese medicine (TCM), and BAI, above all BAI-LZM, is a promising source for the identification of molecules with anti-DN effects.
Literature
1.
2.
Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev. 2002;Suppl 3:S21–6.CrossRef
3.
Adeshara KA, Diwan AG, Tupe RS. Diabetes and complications: cellular signaling pathways, current understanding and targeted therapies. Curr Drug Targets. 2016;17(11):1309–28.PubMedCrossRef
4.
Jin J, Peng C, Wu SZ, Chen HM, Zhang BF. Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats. Acta Pharmacol Sin. 2015;36:831–40.PubMedPubMedCentralCrossRef
5.
Li X, Wang L, Gao X, Li G, Cao H, Song D, et al. Mechanisms of protective effect of Ramulus Mori polysaccharides on renal injury in high-fat diet/Streptozotocin-induced diabetic rats. Cell Physiol Biochem. 2015;37:2125–34.PubMedCrossRef
6.
Van Krieken R, Krepinsky JC. Caveolin-1 in the pathogenesis of diabetic nephropathy: potential therapeutic target? Curr Diab Rep. 2017;17(3):19.PubMedCrossRef
7.
VR A/LBVR, Tan SH, Candasamy M, Bhattamisra SK. Diabetic nephropathy: An update on pathogenesis and drug development. Diabetes Metab Syndr. 2019;13(1):754–62.CrossRef
8.
9.
Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, et al. Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opin Investig Drugs. 2018;27(11):917–30.PubMedCrossRef
10.
Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F, et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes. 2006;55(11):2993–3003.PubMedCrossRef
11.
Nam, J. S., Cho, M. H., Lee, G. T., Park, J. S., Ahn, C. W., Cha,B. S., et al. The activation of NF-κB and AP-1 in peripheral blood mononuclear cells isolated from patients with diabetic nephropathy. Diabetes Res Clin Pract 2008; 81, 25–32.
12.
Yang B, Hodgkinson A, Oates PJ, Millward BA, Demaine AG. High glucose induction of DNA-binding activity of the transcription factor NF-κB in patients with diabetic nephropathy. Biochim Biophys Acta. 2008;1782:295–302.PubMedCrossRef
13.
Goldberg HJ, Whiteside CI, Hart GW, Fantus IG. Posttranslational, reversible O-glycosylation is stimulated by high glucose and mediates plasminogen activator inhibitor-1 gene expression and Sp1 transcriptional activity in glomerular mesangial cells. Endocrinology. 2006;147:222–31.PubMedCrossRef
14.
Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucose-induced nuclear factor-κB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol. 2002;13:894–902.PubMed
15.
Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1358–73.PubMedCrossRef
16.
17.
Bhattacharjee N, Barma S, Konwar N, Dewanjee S, Manna P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: an update. Eur J Pharmacol. 2016;791:8–24.PubMedCrossRef
18.
Sun GD, Li CY, Cui WP, Guo QY, Dong CQ, Zou HB, et al. Review of herbal traditional Chinese medicine for the treatment of diabetic nephropathy. J Diabetes Res. 2016;5749857.
19.
Chen ZJ, Ma F, Sun XM, Zhao XS, Luo R. Renoprotective Effect of a Chinese Herbal Formula, Qidan Dihuang Decoction, on Streptozotocin-Induced Diabetes in Rat. Evid Based Complement Alternat Med. 2018;2018:7321086.PubMedPubMedCentral
20.
Chan KW, Ip TP, Kwong AS, Lui SL, Chan GC, Cowling BJ, et al. Semi-individualised Chinese medicine treatment as an adjuvant management for diabetic nephropathy: a pilot add-on, randomised, controlled, multicentre, open-label pragmatic clinical trial. BMJ Open. 2016;6(8):e010741.PubMedPubMedCentralCrossRef
21.
Yu YL, Lu SS, Yu S, Liu YC, Wang P, Xie L, et al. Huang-lianjie-du- decoction modulates glucagon-like peptide-1 secretion in diabetic rats. J Ethnopharmacol. 2009;124(3):444–9.PubMedCrossRef
22.
Zhu ZZ, Xiong MQ, Lin AZ. Effect of Sanhuang Jiangtang recipe on insulin peripheral resistance in type II diabetes mellitus recipe on insulin peripheral resistance in type II diabetes mellitus. Chin J Integr Med. 1999;5:36–40.
23.
Wu Y, Wang F, Fan L, Zhang W, Wang T, Du Y, Bai X. Baicalin alleviates atherosclerosis by relieving oxidative stress and inflammatory responses via inactivating the NF-κB and p38 MAPK signaling pathways. Biomed Pharmacother. 2018;97:1673–9.PubMedCrossRef
24.
Hang Y, Qin X, Ren T, Cao J. Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Lipids Health Dis. 2018;17(1):146.PubMedPubMedCentralCrossRef
25.
Zakki SA, Cui ZG, Sun L, Feng QW, Li ML, Inadera H. Baicalin Augments Hyperthermia-Induced Apoptosis in U937 Cells and Modulates the MAPK Pathway via ROS Generation. Cell Physiol Biochem. 2018;45(6):2444–60.PubMedCrossRef
26.
Sowndhararajan K, Deepa P, Kim M, Park SJ, Kim S. Neuroprotective and Cognitive Enhancement Potentials of Baicalin: A Review.Brain Sci. 2018; 8(6). pii: E104.
27.
Fretz MM, Dolman ME, Lacombe M, Prakash J, Nguyen TQ, Goldschmeding R, et al. Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. J Control Release. 2008;132(3):200–7.PubMedCrossRef
28.
Poosti F, Yazdani S, Dolman ME, Kok RJ, Chen C, Ding G, et al. Targeted inhibition of renal rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. Eur J Pharmacol. 2012;694(1–3):111–9.PubMedCrossRef
29.
Long L, Qiu H, Cai B, Chen N, Lu X, Zheng S, et al. Hyperglycemia induced testicular damage in type 2 diabetes mellitus rats exhibiting microcirculation impairments associated with vascular endothelial growth factor decreased via PI3K/Akt pathway. Oncotarget. 2018;9(4):5321–36.PubMedPubMedCentralCrossRef
30.
Yuan CM, Nee R, Ceckowski KA, Knight KR, Abbott KC. Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center. Clin Kidney J. 2017;49(2):sfw112–262.CrossRef
31.
Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, et al. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016;14(5):470–81.PubMedPubMedCentralCrossRef
32.
Bus P, Chua JS, Klessens CQF, Zandbergen M, Wolterbeek R, van Kooten C, et al. Complement activation in patients with diabetic nephropathy. Kidney Int Rep. 2017;3(2):302–13.PubMedPubMedCentralCrossRef
33.
Zhu X, Zhang C, Fan Q, Liu X, Yang G, Jiang Y, et al. Inhibiting MicroRNA-503 and MicroRNA-181d with losartan ameliorates diabetic nephropathy in KKAy mice. Med Sci Monit. 2016;22:3902–9.PubMedPubMedCentralCrossRef
34.
Tong X-L, Dong L, Chen L, Zhen Z. Treatment of diabetes using traditional Chinese medicine: past, present and future. Am J Chin Med. 2012;40(5):877–86.PubMedCrossRef
35.
Shi X, Lu XG, Zhan LB, Qi X, Liang LN, Hu SY, et al. The effects of the Chinese medicine ZiBu PiYin recipe on the hippocampus in a rat model of diabetes-associated cognitive decline: a proteomic analysis. Diabetologia. 2011;54(7):1888–99.PubMedCrossRef
36.
Zhao H-L, Sui Y, Qiao C-F, Yip KY, Leung RK, Tsui SK, et al. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes. 2012;61(4):933–43.PubMedPubMedCentralCrossRef
37.
Wen X, Zeng Y, Liu L, Zhang H, Xu W, Li N, et al. Zhenqing recipe alleviates diabetic nephropathy in experimental type 2 diabetic rats through suppression of SREBP-1c. J Ethnopharmacol. 2012;142(1):144–50.PubMedCrossRef
38.
Huang T, Liu Y, Zhang C. Pharmacokinetics and bioavailability enhancement of Baicalin: a review. Eur J Drug Metab Pharmacokinet. 2019;44(2):159–68.PubMedCrossRef
39.
Gong WY, Zhao ZX, Liu BJ, Lu LW, Dong JC. Exploring the chemopreventive properties and perspectives of baicalin and its aglycone baicalein in solid tumors. Eur J Med Chem. 2017;126:844–52.PubMedCrossRef
40.
Xiao Y, Ye J, Zhou Y, Huang J, Liu X, Huang B, et al. Baicalin inhibits pressure overload-induced cardiac fibrosis through regulating AMPK/TGF-β/Smads signaling pathway. Arch Biochem Biophys. 2018;640:37–46.PubMedCrossRef
41.
Zhang J, Zhang H, Deng X, Zhang N, Liu B, Xin S, et al. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice. Life Sci. 2018;192:46–54.PubMedCrossRef
42.
Zheng L, Zhang C, Li L, Hu C, Hu M, Sidikejiang N, et al. Baicalin ameliorates renal fibrosis via inhibition of transforming growth factor β1 production and downstream signal transduction. Mol Med Rep. 2017;15(4):1702–12.PubMedPubMedCentralCrossRef
43.
44.
Masszi A, Kapus A. Smaddening complexity: the role of Smad3 in epithelial-myofibroblast transition. Cells Tissues Organs. 2011;193:41–52.PubMedCrossRef
45.
Pourghasem M, Shafi H, Babazadeh Z. Histological changes of kidney in diabetic nephropathy. Caspian J Intern Med. 2015;6:120–7.PubMedPubMedCentral
46.
Zhang XJ, Deng YX, Shi QZ, He MY, Chen B, Qiu XM. Hypolipidemic effect of the Chinese polyherbal Huanglian Jiedu decoction in type 2 diabetic rats and its possible mechanism. Phytomedicine. 2014;21(5):615–23.PubMedCrossRef
47.
Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf- Beta as the major mediator. J Am Soc Nephrol. 2004;15(Suppl 1):S55–7.PubMedCrossRef
48.
Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124(3):139–52.CrossRef
49.
Parveen A, Jin M, Kim SY. Bioactive phytochemicals that regulate the cellular processes involved in diabetic nephropathy. Phytomedicine. 2018;39:146–59.PubMedCrossRef
50.
Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediat Inflamm. 2012;2012:146154.CrossRef
51.
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327–40.PubMedCrossRef
52.
53.
54.
Fukuda N, Tahira Y, Matsuda H, Matsumoto K. Transforming growth factor β as a treatment target in renal diseases. J Nephrol. 2009;22:708–15.PubMed
55.
Meng XM, Tang PM, Li J, Lan HY. TGF-β/Smad signaling in renal fibrosis. Front Physiol. 2015;19:82–8.
56.
Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325–38.PubMedCrossRef
57.
Chen G, Wang T, Uttarwar L, van Krieken R, Li R, Chen X, Gao B, Ghayur A, Margetts P, Krepinsky JC. SREBP-1 is a novel mediator of TGFβ1 signaling in mesangial cells. J Mol Cell Biol. 2014;6(6):516–30.PubMedCrossRef
58.
Ohtani M, Numazaki M, Yajima Y, Fujita-Yamaguchi Y. Mechanisms of antibody-mediated insulin-like growth factor I receptor (IGF-IR) downregulation in MCF-7 breast cancer cells. Biosci Trends. 2009;3:131–8.PubMed
59.
Zhao Y, Wang Z, Jiang Y, Yang C. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells. Cancer Lett. 2011;313:54–63.PubMedCrossRef
60.
Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159–69.PubMedCrossRef
61.
Chen J, Hou R, Zhang X, Ye Y, Wang Y, Tian J. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. PLoS ONE. 2014;9:e91245.PubMedPubMedCentralCrossRef
62.
63.
Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000;12(1):1–13.PubMedCrossRef
64.
Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):909–16.PubMedCrossRef
65.
Cardoso VG, Gonc Alves GL, Costa-Pessoa JM, Thieme K, Lins BB, FAM C, et al. Angiotensin II-induced podocyteapoptosis is mediated by endoplasmic reticulumstress/PKC- _/p38 MAPK pathway activation and troughincreased Na+/H+ exchanger isoform 1 activity. BMC Nephrol. 2018;19:179.PubMedPubMedCentralCrossRef
66.
Liles JT, Corkey BK, Notte GT, Budas GR, Lansdon EB, Hinojosa-Kirschenbaum F, et al. ASK1 contributes to fibrosisand dysfunction in models of kidney disease. J Clin Invest. 2018;128:4485–500.PubMedPubMedCentralCrossRef
67.
WangW ZPH, XuCG ZXJ, Hu W, Zhang J. Baicalein ameliorate renal interstitial fibrosis by inducing myofibroblast apoptosis in vivo and in vitro. BJU Int. 2016;118:145–52.CrossRef
68.
Juárez-Vázquez CI, Gurrola-Díaz CM, Vargas-Guerrero B, Domínguez-Rosales JA, Rodriguez-Ortiz JF, Barros-Núñez P, Flores-Martínez SE, et al. Insulin Glargine Affects the Expression of Igf-1r, Insr, and Igf-1 Genes in Colon and Liver of Diabetic Rats. Iran J Basic Med Sci. 2018;21(5):489–94.PubMedPubMedCentral
69.
70.
71.
Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, Koya D. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res. 2011;2011:908185.PubMedPubMedCentralCrossRef
72.
Kitada M, Ogura Y, Suzuki T, et al. Avery-low-protein diet ameliorates advanced diabetic nephropathy through autophagy induction by suppression of the mTORC1 pathway in Wistar fatty rats, an animal model of type 2 diabetes and obesity. Diabetologia. 2016;59:1307–17.PubMedCrossRef
73.
Li H, Peng X, Wang Y, Cao S, Xiong L, Fan J, et al. Atg5-mediated autophagy deficiency in proximal tubules promotes cell cycle G2/M arrest and renal fibrosis. Autophagy. 2016;12:1472–86.PubMedPubMedCentralCrossRef
74.
Inoki K, Mori H, Wang J, Suzuki T, Hong SK, Yoshida S, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121:2181–96.PubMedPubMedCentralCrossRef
75.
Hasegawa K, Wakino S, Simic P, Sakamaki Y, Minakuchi H, Fujimura K, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med. 2013;19:1496–504.PubMedPubMedCentralCrossRef
Metadata
Title
Kidney-targeted baicalin-lysozyme conjugate ameliorates renal fibrosis in rats with diabetic nephropathy induced by streptozotocin
Authors
Xiao-peng Zheng
Qing Nie
Jing Feng
Xiao-yan Fan
Yue-lei Jin
Guang Chen
Ji-wei Du
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2020
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-020-01833-6

Other articles of this Issue 1/2020

BMC Nephrology 1/2020 Go to the issue

Research article

Identification of missense and synonymous variants in Iranian patients suffering from autosomal dominant polycystic kidney disease

Research article

Tubular secretion of creatinine and kidney function: an observational study

Research article

Methods to estimate baseline creatinine and define acute kidney injury in lean Ugandan children with severe malaria: a prospective cohort study

Case report

Large calcified renal artery aneurysm in the renal sinus misdiagnosed as an intrapelvic calculus followed by mistakenly performed PCNL: a case report

Research article

Exclusion of pregnancy in dialysis patients: diagnostic performance of human chorionic gonadotropin

Research article

Coagulation parameters are associated with the prognosis of immunoglobulin a nephropathy: a retrospective study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits